
Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …

Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

